Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia

Authors

Publication Details

Journal
Cancer
Published
2024-10-09
DOI
https://doi.org/10.1002/cncr.35579
Citations
1
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.54
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia

Mary Beth Nierengarten
1 citations
Cancer
Acute Lymphoblastic Leukemia research
0.54
article

Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia

Mary Beth Nierengarten
article en
1 citations

Abstract

No abstract available for this paper.
CancerVol. 130(21)
Openalex Percentile: Top 28%
Acute Lymphoblastic Leukemia research
0.54
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia — Mary Beth Nierengarten · Cancer (2024) | TGRS Research Map | TGRS